Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient- based survey on 1133 patients
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient- based survey on 1133 patients
复制标题
DOI：
10.1016/j.leukres.2015.07.004
复制
发表时间：
2015-10-01
影响因子：
2.7
通讯作者：
Alimena, Giuliana
中科院分区：
文献类型：
--
作者：
Breccia, Massimo;Efficace, Fabio;Alimena, Giuliana
随着酪氨酸激酶抑制剂的引入，慢性粒细胞白血病 (CML) 患者的治疗方法发生了革命性的变化，提高了总体生存率和生活质量。最佳的治疗依从性对于最大限度地提高长期结果的益处变得至关重要。据报道，一些证据表明个人因素，例如社会支持、对所用药物和未来的心理和主观看法，可能会影响依从性。我们在此报告专门设计用于评估影响依从性和对未来的看法的因素的调查问卷的结果，该调查问卷在意大利区域会议期间分发给患者。总体而言，共有 1133 名患者填写了问卷：中位年龄为 57 岁。据报告，依从率很高，但 42% 的受访患者承认，他们偶尔会推迟用药，58% 的患者主要因为健忘而停止治疗。大多数患者与私人医生讨论了坚持的重要性，并获得了有关疾病和治疗的足够信息，但希望更多地讨论有关不适、焦虑和对未来的恐惧。总结个人服药依从性并估算患者平均每月有多少天没有服药，大多数回答少于3天（55%），只有少数（4%）承认超过7天。在接受关于停药的采访时，49%的患者回答不会停药，因为担心失去迄今为止取得的所有成果。这项研究表明，收到的信息越多，满意度越高，但需要改善有关未来可能的无治疗缓解的沟通。 (C) 2015 Elsevier Ltd. 保留所有权利。
Therapeutic approach for chronic myeloid leukemia (CML) patients has undergone a revolutionary change with the introduction of tyrosine kinase inhibitors, which improved overall survival and quality of life. Optimal therapy adherence has become of paramount importance to maximize the benefits in the long-term outcome. Several evidences have been reported that personal factors, such as social support, psychological and subjective perceptions about the drug used and the future, could influence adherence. We here report the results of a questionnaire specifically designed to evaluate factors influencing adherence and perceptions about the future, distributed to patients during regional Italian meetings. Overall, 1133 patients compiled the questionnaire: median age was 57 years. High rate of adherence was reported, but 42% of interviewed patients admitted that they had occasionally postponed a dose and 58% had discontinued therapy mainly for forgetfulness. The majority of patients discussed with personal physician about the importance of adherence and received sufficient information about illness and treatment, but would like to have discussed more about discomfort, anxiety and fear of the future. Summarizing personal drug compliance and estimating how many days a month, on average, the patients did not take the drug, the majority answered that it was less than 3 days (55%) and only a minority (4%) admitted that it was more than 7 days. Interviewed about discontinuation, 49% of patients answered that wouldn't interrupt because of fear of losing all the results achieved so far. This study suggests a higher level of satisfaction with more information received but the need of improving communication about possible future treatment free remission. (C) 2015 Elsevier Ltd. All rights reserved.